Revenues from Baxter's BioScience business totaled $1.1 billion and increased 14 percent over the prior-year period, driven by double-digit growth across multiple product categories. Sales of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a therapy used in the treatment of hemophilia A, exceeded $300 million in the quarter as the company continued to drive global conversion to the therapy. Robust sales of plasma therapeutics, antibody therapy products for the treatment of immunodeficiencies, and biosurgery products used for hemostasis, tissue sealing and tissue repair also contributed to the business' performance.
Revenues from Baxter's Medication Delivery business grew 10 percent to $1.0 billion in the third quarter, primarily as a result of strong global sales of anesthesia, intravenous solutions and parenteral nutrition products. Renal revenues of $0.6 billion increased 8 percent, as the company continued to realize solid gains in the number of peritoneal dialysis patients it serves, particularly in developing countries.
"The company remains focused on executing our strategies and continuing to build shareholder value," said Robert L. Parkinson, Jr., chairman and chief executive officer. "Our consistent, strong operational performance, driven by our focus on gross margin expansion affords us the opportunity to accelerate investments to grow our business for the longer-term, while at the same time, allowing us to meet or exceed our shorter-term objectives."
Baxter's investment in research a
|SOURCE Baxter International Inc.|
Copyright©2007 PR Newswire.
All rights reserved